Enhanced Nitric Oxide-Releasing Materials

增强一氧化氮释放材料

• 批准号: 6896808
• 负责人: Scott I Merz
• 金额: $ 47.88万
• 依托单位: MC3, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-04-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6896808
• 关键词: bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; biotechnology; cardiovascular prosthesis; cell adhesion; circulatory assist; medical implant science; nitric oxide; platelet activation; polymers; reducing agents; sheep; surface coating

DESCRIPTION (provided by applicant): The goal of this project is to develop a family of nitric oxide-releasing materials (NORM), formed by adding nitric oxide (NO) donor compounds to polymers. The enhanced NORM developed in Phase I of this effort released NO for a prolonged period of time, at rates exceeding the release of the normal endothelium. The NO donor formulations from Phase I will be combined with commercially-available biopolymers. The resulting NORM will be used to treat prosthetic vascular grafts, which will be tested in long-term implantation experiments in sheep to evaluate the efficacy of the materials in prolonging patency. The goal of the project is to focus on developing a prosthetic vascular graft with improved long-term patency as a commercial application of NORM. The advances in NORM technology achieved in pursuit of this goal is expected to lead to other applications of this technology. If successful, NORM technology has the potential to contribute substantially to the field of prosthetic vascular grafts. The number of grafts implanted for hemodialysis access alone is a sizeable and growing market. Failure rates with prosthetic grafts are approximately 40% after one year for lower extremity bypass and hemodialysis grafts. Early thrombosis is common, as is long-term failure due to intimal hyperplasia. Nitric oxide released from NORM may potentially contribute to preventing short- and long-term failure modes. A pilot study showed promising results for short-term benefits.

描述（由申请人提供）： 该项目的目标是开发一系列一氧化氮释放材料（NORM），通过向聚合物中添加一氧化氮（NO）供体化合物形成。在这一努力的第一阶段中开发的增强的NORM以超过正常内皮释放的速率释放NO持续较长的时间。来自阶段I的NO供体制剂将与市售生物聚合物组合。由此产生的NORM将用于治疗人工血管移植物，将在绵羊的长期植入实验中进行测试，以评估材料在延长通畅性方面的功效。该项目的目标是专注于开发一种具有改善的长期通畅性的人工血管移植物，作为NORM的商业应用。在追求这一目标的过程中，NORM技术取得了进步，预计将导致该技术的其他应用。 如果成功，NORM技术有可能为人工血管移植领域做出重大贡献。仅为血液透析通路植入的移植物数量是一个相当大的且不断增长的市场。对于下肢旁路和血液透析移植物，一年后人工移植物的失败率约为40%。早期血栓形成是常见的，由于内膜增生导致的长期失败也是常见的。NORM释放的一氧化氮可能有助于防止短期和长期失效模式。一项试点研究显示，短期效益方面的成果很有希望。